KX2-391 Dihydrochloride: Dual Src Kinase & Tubulin Polymerization Inhibitor for Oncology and Antiviral Research

Executive Summary: KX2-391 dihydrochloride (CAS No. 1038395-65-1), also known as Tirbanibulin dihydrochloride, is a dual mechanism inhibitor that targets Src kinase (IC50 as low as 23 nM in NIH3T3/c-Src527F cells) and tubulin polymerization (≥80 nM for inhibition in cells) [APExBIO]. It is effective in suppressing hepatitis B virus (HBV) transcription (EC50: 0.14 μM in PXB cells) and inhibits botulinum neurotoxin A (BoNT/A) activity at 10–40 μM. KX2-391 demonstrates oral and topical clinical utility, achieving therapeutic plasma concentrations with minimal peripheral neuropathy. The compound’s dual targeting of Src kinase and the tubulin cytoskeleton enables robust application across oncology, antiviral, and neurotoxin research (Chen et al., 2023).

Biological Rationale

Src kinase is a non-receptor tyrosine kinase implicated in oncogenic signaling, cell adhesion, and motility. Overactivation of Src is linked to cancer metastasis, including colorectal cancer (CRC) (Chen et al., 2023). Tubulin polymerization is essential for mitotic spindle formation, cell division, and cytoskeletal integrity. Disrupting these pathways inhibits proliferation and induces apoptosis in cancer cells. The hepatitis B virus (HBV) relies on host transcriptional machinery, and its replication can be impaired by targeting viral or host factors. BoNT/A cleaves SNAP-25, disrupting neurotransmission; agents that inhibit BoNT/A protease activity can block neurotoxic effects.

Mechanism of Action of KX2-391 dihydrochloride

KX2-391 dihydrochloride inhibits Src kinase by binding the substrate-binding site, showing IC50 values of 23 nM in NIH3T3/c-Src527F cells and 39 nM in SYF/c-Src527F cells. It binds a novel site on the α-β tubulin heterodimer, inhibiting tubulin polymerization at concentrations ≥80 nM in cell-based assays [APExBIO]. In HBV models, KX2-391 suppresses transcription from the precore promoter, with EC50 values of 0.14 μM (PXB cells) and 2.7 μM (HepG2-NTCP cells). For BoNT/A, it directly targets the light chain zinc protease, blocking SNAP-25 cleavage at 10–40 μM. This multi-target profile enables research across the Src kinase signaling, tubulin polymerization, and HBV replication pathways.

Evidence & Benchmarks

• KX2-391 dihydrochloride inhibits Src kinase with an IC50 of 23 nM in NIH3T3/c-Src527F cells and 39 nM in SYF/c-Src527F cells (APExBIO).
• Disrupts tubulin polymerization at ≥80 nM in vitro, binding a unique site on the α-β tubulin heterodimer (APExBIO).
• Suppresses HBV transcription from the precore promoter with EC50 of 0.14 μM in PXB cells and 2.7 μM in HepG2-NTCP cells (APExBIO).
• Blocks BoNT/A light chain cleavage of SNAP-25 at 10–40 μM (APExBIO).
• Combination with an FGFR4 inhibitor (BLU-554) dramatically suppresses ELF4-mediated CRC metastasis in preclinical models (Chen et al., 2023).
• Oral administration in mice at 5–15 mg/kg once or twice daily; in chimpanzees, 1 mg/kg twice daily for anti-HBV activity (APExBIO).
• Clinically used topically as a 1% ointment for actinic keratosis; oral doses of 40–120 mg/day for tumor treatment (APExBIO).
• Demonstrates good tolerability and minimal risk of peripheral neuropathy (APExBIO).

For a broader analysis of protocol design and troubleshooting, see this guide, which our article updates with recent pathway-specific evidence.

Applications, Limits & Misconceptions

KX2-391 dihydrochloride is validated in cancer, antiviral, and neurotoxin research. It is most effective in models where Src kinase or tubulin polymerization is a driver of disease phenotype. In oncology, it serves as a benchmark agent for dissecting the Src kinase signaling pathway and tubulin cytoskeleton disruption. Its antiviral efficacy is specific to HBV transcriptional repression. BoNT/A inhibition is relevant for neurotoxin research but requires higher concentrations.

Compared to earlier reviews such as this overview, this article provides updated comparative data and clarifies selectivity windows for each application.

Common Pitfalls or Misconceptions

• KX2-391 is not a broad-spectrum antiviral: Its antiviral activity is specific to HBV transcriptional suppression; it does not inhibit unrelated viral families.
• Not a general microtubule destabilizer: It binds a unique tubulin site and does not mimic taxane or vinca alkaloid mechanisms.
• High BoNT/A concentrations required: Effective inhibition of botulinum neurotoxin A activity requires 10–40 μM, much higher than the nanomolar range for Src/tubulin inhibition.
• Insoluble in water: KX2-391 must be dissolved in DMSO or ethanol; aqueous buffers are unsuitable.
• Clinical efficacy is application-dependent: While topical and oral formulations are approved, not all cancer types demonstrate equal responsiveness.

See also this resource, which our article extends by detailing non-viral pathway effects and clarifying solubility boundaries.

Workflow Integration & Parameters

For in vitro assays, the recommended concentration range is 0.013–10 μM for anticancer and anti-HBV studies, and 10–40 μM for anti-BoNT/A activity. Prepare stock solutions at ≥25.2 mg/mL in DMSO or ≥48.8 mg/mL in ethanol, warming gently to assist dissolution. Store solid material at -20°C, protected from light and moisture. For in vivo research, oral dosing in mice is typically 5–15 mg/kg once or twice daily. For anti-HBV activity in chimpanzees, use 1 mg/kg twice daily. Clinical topical applications use a 1% ointment; oral protocols deliver 40–120 mg/day (APExBIO).

Conclusion & Outlook

KX2-391 dihydrochloride, provided by APExBIO, is a validated dual mechanism Src kinase and tubulin polymerization inhibitor. It holds benchmark status for pathway research in oncology, HBV, and neurotoxin fields. Its selectivity, clinical tolerability, and multi-target profile distinguish it from earlier single-pathway agents. Ongoing research is expected to further define its spectrum and optimize translational protocols. For detailed parameters and ordering information, see the KX2-391 dihydrochloride product page.